Children With HIV and Asthma (CHIVAS)

The HIV Netherlands Australia Thailand Research Collaboration

Status: Completed

Conditions: T Cell Response to Asthma in HIV-infected Patients Before and After Starting Treatment

Treatments: Drug: HAART

Study type: Interventional

Funder types: Other

Identifiers

NCT01644370

HIV-NAT 102

Details and patient eligibility

About

To explore allergen-specific effector and regulatory T cell response in HIV-infected children before and after HAART initiation

Full description

Recently, US investigators have observed that HIV-infected (HIV+) children on highly active antiretroviral therapy (HAART) have a much greater cumulative incidence of asthma.Regulatory T cells may mitigate the pathogenicity of asthma through the suppression of Th2 responses. Since asthma is predominantly a TH2 mediated condition, we propose that new onset of asthma after HAART in HIV- infected children may be secondary to dysregulated immune reconstitution. The restoration of CD4+ T cell-mediated immunity in HIV+ patients treated with HAART may lead to airway inflammation, narrowing, hyperresponsiveness, and possibly remodeling.

The increased incidence of asthma in HIV-infected children treated with HAART is likely secondary to multiple factors that may include hypersensitivity to certain aeroallergens, dysregulation of effector and regulatory T cell response, as well as the imbalance of TH1 vs. TH2 cytokines. Therefore this study will identify the immunopathogenesis of increased airway hyperresponsiveness in HIV-positive patients.

Enrollment: 20 patients

Sex: All

Ages: 2 to 18 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

1. Children aged 2-18 years
2. Parent signed inform consent and children signed assent form
3. Children who are starting highly active antiretroviral therapy (HAART) due to clinical indication or switching HAART due to treatment failure within 45 days after screening visit

Exclusion criteria

1. Pregnancy
2. History of chronic lung disease including lymphoid interstitial pneumonitis (LIP), and bronchopulmonary dysplasia (BPD).
3. Active opportunistic infections i.e. pulmonary tuberculosis, PCP, pneumonia
4. Conditions limiting ability of subject to comprehend questionnaires (i.e. mental retardation).

Trial design

Primary purpose: Basic Science

Allocation: Non-Randomized

Interventional model: Parallel Assignment

Masking: None (Open label)

---

20 participants in 3 patient groups

HIV positive with aeroallergen

Other group

Description:

positive for aeroallergen at baseline

Treatment:

Drug: HAART

HIV positive without aeroallergen

Other group

Description:

negative for aeroallergen at baseline

Treatment:

Drug: HAART

control

No Intervention group

Description:

HIV negative children (n=10)